LOS ANGELES (KABC) -- New technology that's allowing doctors to pinpoint prostate cancer long before it becomes a threat is now widely available. A former firefighter mentioned how this new imaging ...

Multiparametric MRI detects more local recurrences after prostatectomy than prostate-specific membrane antigen PET-CT, with the two showing only moderate agreement.

Treat or observe? Dr. Joseph Renzulli of Yale School of Medicine shares how he assesses and counsels elderly patients referred for treatment because of elevated PSA levels. (2:44) Fighting Fatigue in ...

Among 134 men undergoing radical prostatectomy, PSMA PET accurately identified pathological tumor stage in 45% of patients compared with 28% of patients with MRI (P=0.003), reported Adam Kinnaird, MD, ...

@2024 - All Right Reserved.

A new radioactive diagnostic agent for use in prostate cancer has been approved by the US Food and Drug Administration (FDA). The product, Gallium 68 PSMA-11 (Ga 68 PSMA-11), has been approved for ...

Visual Abstract. Overall survival for patients treated with salvage radiotherapy: real world data from an entire country. A patient with biochemical recurrence after radical prostatectomy and no ...

Gozetotide is a drug for diagnostic application in adults with prostate cancer. It is currently the only diagnostic agent that recognizes PSMA-positive prostate cancer and can therefore identify ...

Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify [email protected] if there are concerns regarding accuracy of the transcription.

A multicenter study led by London Health Sciences Centre Research Institute (LHSCRI), Lawson Research Institute of St. Joseph's Health Care London (Lawson), and University Health Network (UHN) has ...